Browsing Tag

DAY101

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of…

Eli Pacheco Jun 4, 2023 0

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in…

Health

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib…

Eli Pacheco Jun 13, 2022 0

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib Topline results from the full…